Search: WFRF:(Madelon R.) >
A randomised, open-...
A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis : The UPSIDE study protocol
-
- Spierings, Julia (author)
- University Medical Center Utrecht
-
- Van Rhenen, Anna (author)
- University Medical Center Utrecht
-
- Welsing, Paco M.W. (author)
- University Medical Center Utrecht
-
show more...
-
- Marijnissen, Anne C.A. (author)
- University Medical Center Utrecht
-
- De Langhe, Ellen (author)
- University Hospitals Leuven
-
- Del Papa, Nicoletta (author)
- Istituto Ortopedico Gaetano Pini
-
- Dierickx, Daan (author)
- University Hospitals Leuven
-
- Gheorghe, Karina R. (author)
- Karolinska Institute,Karolinska University Hospital
-
- Henes, Joerg (author)
- University Hospital of Tubingen
-
- Hesselstrand, Roger (author)
- Lund University,Lunds universitet,Forskargruppen för systemisk skleros, Lund,Forskargrupper vid Lunds universitet,Lund Systemic Sclerosis Research Group,Lund University Research Groups,Skåne University Hospital
-
- Kerre, Tessa (author)
- Ghent University Hospital
-
- Ljungman, Per (author)
- Karolinska Institutet
-
- Van De Loosdrecht, Arjan A. (author)
- Amsterdam UMC - Vrije Universiteit Amsterdam
-
- Marijt, Erik W.A.F. (author)
- Leiden University Medical Centre
-
- Mayer, Miro (author)
- University Hospital Centre Zagreb
-
- Schmalzing, Marc (author)
- University Hospital of Wϋrzburg
-
- Schroers, Roland (author)
- Ruhr-University Bochum
-
- Smith, Vanessa (author)
- Ghent University Hospital,Ghent University
-
- Voll, Reinhard E. (author)
- University Medical Center Freiburg
-
- Vonk, Madelon C. (author)
- Radboud University Medical Center
-
- Voskuyl, Alexandre E. (author)
- Amsterdam UMC - Vrije Universiteit Amsterdam
-
- De Vries-Bouwstra, Jeska K. (author)
- Leiden University Medical Centre
-
- Walker, Ulrich A. (author)
- University Hospital Basel
-
- Wuttge, Dirk M. (author)
- Lund University,Lunds universitet,Forskargruppen för systemisk skleros, Lund,Forskargrupper vid Lunds universitet,Lund Systemic Sclerosis Research Group,Lund University Research Groups,Skåne University Hospital
-
- Van Laar, Jacob M. (author)
- University Medical Center Utrecht
-
show less...
-
(creator_code:org_t)
- 2021-03-18
- 2021
- English.
-
In: BMJ Open. - : BMJ. - 2044-6055. ; 11:3
- Related links:
-
http://dx.doi.org/10... (free)
-
show more...
-
https://bmjopen.bmj....
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- Introduction Systemic sclerosis (SSc) is a chronic, autoimmune connective tissue disease associated with high morbidity and mortality, especially in diffuse cutaneous SSc (dcSSc). Currently, there are several treatments available in early dcSSc that aim to change the disease course, including immunosuppressive agents and autologous haematopoietic stem cell transplantation (HSCT). HSCT has been adopted in international guidelines and is offered in current clinical care. However, optimal timing and patient selection for HSCT are still unclear. In particular, it is unclear whether HSCT should be positioned as upfront therapy or rescue treatment for patients refractory to immunosuppressive therapy. We hypothesise that upfront HSCT is superior and results in lower toxicity and lower long-term medical costs. Therefore, we propose this randomised trial aiming to determine the optimal treatment strategy for early dcSSc by comparing two strategies used in standard care: (1) upfront autologous HSCT versus (2) immunosuppressive therapy (intravenous cyclophosphamide pulse therapy followed by mycophenolate mofetil) with rescue HSCT in case of treatment failure. Methods and analysis The UPSIDE (UPfront autologous hematopoietic Stem cell transplantation vs Immunosuppressive medication in early DiffusE cutaneous systemic sclerosis) study is a multicentre, randomised, open-label, controlled trial. In total, 120 patients with early dcSSc will be randomised. The primary outcome is event-free survival at 2 years after randomisation. Secondary outcomes include serious adverse events, functional status and health-related quality of life. We will also evaluate changes in nailfold capillaroscopy pattern, pulmonary function, cardiac MR and high-resolution CT of the chest. Follow-up visits will be scheduled 3-monthly for 2 years and annually in the following 3 years. Ethics and dissemination The study was approved by the Dutch Central Committee on Research Concerning Human Subjects (NL72607.041.20). The results will be disseminated through patient associations and conventional scientific channels. Trial registration numbers NCT04464434; NL 8720.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Reumatologi och inflammation (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Rheumatology and Autoimmunity (hsv//eng)
Keyword
- bone marrow transplantation
- clinical trials
- immunology
- rheumatology
- transplant medicine
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
-
BMJ Open
(Search for host publication in LIBRIS)
To the university's database
- By the author/editor
-
Spierings, Julia
-
Van Rhenen, Anna
-
Welsing, Paco M. ...
-
Marijnissen, Ann ...
-
De Langhe, Ellen
-
Del Papa, Nicole ...
-
show more...
-
Dierickx, Daan
-
Gheorghe, Karina ...
-
Henes, Joerg
-
Hesselstrand, Ro ...
-
Kerre, Tessa
-
Ljungman, Per
-
Van De Loosdrech ...
-
Marijt, Erik W.A ...
-
Mayer, Miro
-
Schmalzing, Marc
-
Schroers, Roland
-
Smith, Vanessa
-
Voll, Reinhard E ...
-
Vonk, Madelon C.
-
Voskuyl, Alexand ...
-
De Vries-Bouwstr ...
-
Walker, Ulrich A ...
-
Wuttge, Dirk M.
-
Van Laar, Jacob ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Rheumatology and ...
- Articles in the publication
-
BMJ Open
- By the university
-
Lund University
-
Karolinska Institutet